Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,419
archived clinical trials in
Pulmonary

Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated:  3/20/2018
Los Angeles County/University of Southern California Medical Center
mi
from
Los Angeles, CA
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated: 3/20/2018
Los Angeles County/University of Southern California Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated:  3/20/2018
University of California at Los Angeles
mi
from
Los Angeles, CA
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated: 3/20/2018
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated:  3/20/2018
Mayo Clinic
mi
from
Jacksonville, FL
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated: 3/20/2018
Mayo Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated:  3/20/2018
Emory University
mi
from
Atlanta, GA
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated: 3/20/2018
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated:  3/20/2018
University of Kentucky Medical Center
mi
from
Lexington, KY
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated: 3/20/2018
University of Kentucky Medical Center
mi
from
Lexington, KY
Click here to add this to my saved trials
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated:  3/20/2018
Saint Agnes Hospital
mi
from
Baltimore, MD
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated: 3/20/2018
Saint Agnes Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated:  3/20/2018
Johns Hopkins University
mi
from
Baltimore, MD
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated: 3/20/2018
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated:  3/20/2018
Brigham and Women's Hosp
mi
from
Boston, MA
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated: 3/20/2018
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated:  3/20/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated: 3/20/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated:  3/20/2018
Baystate Medical Center
mi
from
Springfield, MA
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated: 3/20/2018
Baystate Medical Center
mi
from
Springfield, MA
Click here to add this to my saved trials
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated:  3/20/2018
University of Michigan Medical Center
mi
from
Ann Arbor, MI
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated: 3/20/2018
University of Michigan Medical Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated:  3/20/2018
Saint Joseph Mercy Ann Arbor
mi
from
Ypsilanti, MI
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated: 3/20/2018
Saint Joseph Mercy Ann Arbor
mi
from
Ypsilanti, MI
Click here to add this to my saved trials
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated:  3/20/2018
The Mayo Clinic
mi
from
Rochester, MN
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated: 3/20/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated:  3/20/2018
Regions Hospital
mi
from
Saint Paul, MN
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated: 3/20/2018
Regions Hospital
mi
from
Saint Paul, MN
Click here to add this to my saved trials
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated:  3/20/2018
Montefiore Medical Center
mi
from
Bronx, NY
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated: 3/20/2018
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated:  3/20/2018
Northwell Health
mi
from
Manhasset, NY
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated: 3/20/2018
Northwell Health
mi
from
Manhasset, NY
Click here to add this to my saved trials
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated:  3/20/2018
Columbia University Medical Center
mi
from
New York, NY
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated: 3/20/2018
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated:  3/20/2018
Duke Univ Med Ctr
mi
from
Durham, NC
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated: 3/20/2018
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated:  3/20/2018
East Carolina University
mi
from
Greenville, NC
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated: 3/20/2018
East Carolina University
mi
from
Greenville, NC
Click here to add this to my saved trials
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated:  3/20/2018
University of Cincinnati Medical Center
mi
from
Cincinnati, OH
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated: 3/20/2018
University of Cincinnati Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated:  3/20/2018
Cleveland Clinic
mi
from
Cleveland, OH
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated: 3/20/2018
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated:  3/20/2018
Ohio State University Medical Center
mi
from
Columbus, OH
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated: 3/20/2018
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated:  3/20/2018
Oregan Health and Science University Hospital
mi
from
Portland, OR
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated: 3/20/2018
Oregan Health and Science University Hospital
mi
from
Portland, OR
Click here to add this to my saved trials
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated:  3/20/2018
Temple University Hospital
mi
from
Philadelphia, PA
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated: 3/20/2018
Temple University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated:  3/20/2018
Intermountain Medical Center
mi
from
Murray, UT
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated: 3/20/2018
Intermountain Medical Center
mi
from
Murray, UT
Click here to add this to my saved trials
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated:  3/20/2018
University Of Utah Hospital
mi
from
Salt Lake City, UT
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated: 3/20/2018
University Of Utah Hospital
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated:  3/20/2018
Harborview Medical Center
mi
from
Seattle, WA
Severe ARDS: Generating Evidence
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Status: Enrolling
Updated: 3/20/2018
Harborview Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease
A Phase II, Two-Part, Randomised, Multi-Centre, Multinational, Double-Blind, Placebo-Controlled, Parallel Group Study to Compare the Efficacy and Safety of BCT197 When Added on to Standard of Care for the Treatment of Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease Requiring Hospitalisation in Adults
Status: Enrolling
Updated:  3/21/2018
Mereo Investigator Site
mi
from
Michigan City, IN
Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease
A Phase II, Two-Part, Randomised, Multi-Centre, Multinational, Double-Blind, Placebo-Controlled, Parallel Group Study to Compare the Efficacy and Safety of BCT197 When Added on to Standard of Care for the Treatment of Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease Requiring Hospitalisation in Adults
Status: Enrolling
Updated: 3/21/2018
Mereo Investigator Site
mi
from
Michigan City, IN
Click here to add this to my saved trials
Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease
A Phase II, Two-Part, Randomised, Multi-Centre, Multinational, Double-Blind, Placebo-Controlled, Parallel Group Study to Compare the Efficacy and Safety of BCT197 When Added on to Standard of Care for the Treatment of Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease Requiring Hospitalisation in Adults
Status: Enrolling
Updated:  3/21/2018
Mereo Research Site
mi
from
Baltimore, MD
Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease
A Phase II, Two-Part, Randomised, Multi-Centre, Multinational, Double-Blind, Placebo-Controlled, Parallel Group Study to Compare the Efficacy and Safety of BCT197 When Added on to Standard of Care for the Treatment of Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease Requiring Hospitalisation in Adults
Status: Enrolling
Updated: 3/21/2018
Mereo Research Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease
A Phase II, Two-Part, Randomised, Multi-Centre, Multinational, Double-Blind, Placebo-Controlled, Parallel Group Study to Compare the Efficacy and Safety of BCT197 When Added on to Standard of Care for the Treatment of Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease Requiring Hospitalisation in Adults
Status: Enrolling
Updated:  3/21/2018
Mereo Research Site
mi
from
Milwaukee, WI
Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease
A Phase II, Two-Part, Randomised, Multi-Centre, Multinational, Double-Blind, Placebo-Controlled, Parallel Group Study to Compare the Efficacy and Safety of BCT197 When Added on to Standard of Care for the Treatment of Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease Requiring Hospitalisation in Adults
Status: Enrolling
Updated: 3/21/2018
Mereo Research Site
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease
A Phase II, Two-Part, Randomised, Multi-Centre, Multinational, Double-Blind, Placebo-Controlled, Parallel Group Study to Compare the Efficacy and Safety of BCT197 When Added on to Standard of Care for the Treatment of Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease Requiring Hospitalisation in Adults
Status: Enrolling
Updated:  3/21/2018
Mereo Research Site
mi
from
Dupnitsa,
Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease
A Phase II, Two-Part, Randomised, Multi-Centre, Multinational, Double-Blind, Placebo-Controlled, Parallel Group Study to Compare the Efficacy and Safety of BCT197 When Added on to Standard of Care for the Treatment of Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease Requiring Hospitalisation in Adults
Status: Enrolling
Updated: 3/21/2018
Mereo Research Site
mi
from
Dupnitsa,
Click here to add this to my saved trials
Harmonica Playing Improves Quality of Life in Patients With COPD
Harmonica Playing Improves Inspiratory and Expiratory Muscle Strength, Reduces Shortness of Breath With Activity, and Improves Quality of Life in Patients With COPD
Status: Enrolling
Updated:  3/21/2018
Baylor University Medical Center
mi
from
Dallas, TX
Harmonica Playing Improves Quality of Life in Patients With COPD
Harmonica Playing Improves Inspiratory and Expiratory Muscle Strength, Reduces Shortness of Breath With Activity, and Improves Quality of Life in Patients With COPD
Status: Enrolling
Updated: 3/21/2018
Baylor University Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated:  3/21/2018
Clinical Research Facility
mi
from
Athens, AL
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated: 3/21/2018
Clinical Research Facility
mi
from
Athens, AL
Click here to add this to my saved trials
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated:  3/21/2018
Clinical Research Facility
mi
from
Birmingham, AL
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated: 3/21/2018
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated:  3/21/2018
Clinical Research Facility
mi
from
Dothan, AL
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated: 3/21/2018
Clinical Research Facility
mi
from
Dothan, AL
Click here to add this to my saved trials
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated:  3/21/2018
Clinical Research Facility
mi
from
Phoenix, AZ
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated: 3/21/2018
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated:  3/21/2018
Clinical Research Facility
mi
from
Tucson, AZ
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated: 3/21/2018
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated:  3/21/2018
Clinical Research Facility
mi
from
Anaheim, CA
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated: 3/21/2018
Clinical Research Facility
mi
from
Anaheim, CA
Click here to add this to my saved trials
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated:  3/21/2018
Clinical Research Facility
mi
from
Gold River, CA
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated: 3/21/2018
Clinical Research Facility
mi
from
Gold River, CA
Click here to add this to my saved trials
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated:  3/21/2018
Clinical Research Facility
mi
from
Palm Springs, CA
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated: 3/21/2018
Clinical Research Facility
mi
from
Palm Springs, CA
Click here to add this to my saved trials
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated:  3/21/2018
Clinical Research Facility
mi
from
Sacramento, CA
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated: 3/21/2018
Clinical Research Facility
mi
from
Sacramento, CA
Click here to add this to my saved trials
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated:  3/21/2018
Clinical Research Facility
mi
from
San Diego, CA
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated: 3/21/2018
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated:  3/21/2018
Clinical Research Facility
mi
from
Boulder, CO
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated: 3/21/2018
Clinical Research Facility
mi
from
Boulder, CO
Click here to add this to my saved trials
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated:  3/21/2018
Clinical Research Facility
mi
from
Colorado Springs, CO
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated: 3/21/2018
Clinical Research Facility
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated:  3/21/2018
Clinical Research Facility
mi
from
Littleton, CO
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated: 3/21/2018
Clinical Research Facility
mi
from
Littleton, CO
Click here to add this to my saved trials
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated:  3/21/2018
Clinical Research Facility
mi
from
Hamden, CT
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated: 3/21/2018
Clinical Research Facility
mi
from
Hamden, CT
Click here to add this to my saved trials
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated:  3/21/2018
Clinical Research Facility
mi
from
Clearwater, FL
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated: 3/21/2018
Clinical Research Facility
mi
from
Clearwater, FL
Click here to add this to my saved trials
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated:  3/21/2018
Clinical Research Facility
mi
from
DeLand, FL
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated: 3/21/2018
Clinical Research Facility
mi
from
DeLand, FL
Click here to add this to my saved trials
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated:  3/21/2018
Clinical Research Facility
mi
from
Hialeah, FL
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated: 3/21/2018
Clinical Research Facility
mi
from
Hialeah, FL
Click here to add this to my saved trials
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated:  3/21/2018
Clinical Research Facility
mi
from
Miami, FL
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated: 3/21/2018
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials